Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ensartinib - Betta Pharmaceuticals/Xcovery

Next Previous
Drug Profile

Ensartinib - Betta Pharmaceuticals/Xcovery

Alternative Names: Ensacove; Ensartinib Hydrochloride; X-396

Latest Information Update: 19 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xcovery
  • Developer AstraZeneca; Betta Pharmaceuticals Co Ltd; Cancer Research Institute; Ludwig Institute for Cancer Research; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Xcovery Holdings
  • Class Antineoplastics; Piperazines; Pyridazines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; EphA2 receptor antagonists; Proto-oncogene protein c-met inhibitors; ROS1 protein inhibitors; TrkA receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II CNS cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 10 Nov 2025 Launched for Non-small cell lung cancer (First-line therapy) in USA (PO) prior to November 2025 (Betta Pharmaceuticals pipeline, November 2025)
  • 09 Jul 2024 Betta Pharmaceuticals plans a phase I pharmacokinetics trial (In volunteers) in China (PO) (NCT06492525)
  • 14 Mar 2024 US FDA accepts NDA for ensartinib for ALK-positive non-small cell lung cancer (NSCLC) for review

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top